A randomized, double-blinded study of comparison of 2.5 mg/L versus 3.75 mg/L of methoxsalen concentration for bath-PUVA in psoriasis vulgaris
Keywords:
Phototherapy, psoriasis, methoxsalen concentrationAbstract
Introduction Photochemotherapy includes use of exogenous photosensitizer along with exposure to ultraviolet radiation {P- psoralen (photosensitizer) + UVA (ultraviolet radiation A)} which can be administered in form of oral or topical solution. Bath PUVA involves delivering psoralen through immersion in water containing methoxasalen (photosensitizer) followed by exposure to UVA radiation. We carried out this study in patients with psoriasis vulgaris to find the difference in response, adverse effects profile and duration of remission in patients treated with lower dose versus standard dose being used. Aim This was a prospective, randomized, double blinded study to compare the efficacy and side effects of low concentration i.e. 2.5mg/L versus standard concentration i.e. 3.75mg/L in patients suffering from psoriasis vulgaris with more than 20% body surface area involved. Methods Total of 19 patients were included, they were divided using block randomization technique into two groups; group A and group B consisting of 9 patients and 10 patients respectively. Group A patients were exposed to low dose of psoralean (2.5 mg/L) while group B patients were given 3.75 mg/L of methoxasalen. Phototherapy sessions were done at an interval of 48-72 hours for a total of 14 sessions and PASITUL (TUL) (TUL- Trunk, upper limb and lower limb) was calculated at every 4th session. Analysis of PASITUL was done using 3 point scale for PASI and any side effects during the therapy were noted. Results All the patients in both the groups achieved complete remission and there was no significant difference between cumulative UVA dose and duration of therapy as well. All the 19 patients irrespective of the concentration of 8-MOP (8-methoxypsoralean) achieved complete remission. 6 out of 19 patients had recurrence of psoriasis and 4 of these patients belonged to low concentration group while 2 were treated with high concentration and also remission was longer for patients in high concentration group. Conclusion 2.5 mg/L concentration of psoralen is as efficacious as 3.75mg/L with no significant difference in terms of side effects, number of sessions and cumulative dose of UVA radiation but treatment with 3.75mg/L leads to longer duration of clinical remission as compared to 2.5 mg/L.References
Griffiths CE, Barker JN. Pathogenesis and clinical features of psoriasis. Lancet 2007; 370(9583): 263-71.
Guidelines of care for the treatment of psoriasis with phototherapy and photochemotherapy. J Am Acad Dermatol. 2010; 62(1): 114–35.
Pai SB, Shetty S. Guidelines for bath PUVA, bathing suit PUVA and soak PUVA. Indian J Dermatol Venereol Leprol 2015; 81: 559-67.
Vongthongsri R, Konschitzky R, Seeber A, Treitl C, Hönigsmann H, Tanew A. Randomized, double-blind comparison of 1 mg/L versus 5 mg/L methoxsalen bath-PUVA therapy for chronic plaque-type psoriasis. J Am Acad Dermatol. 2006; 55(4): 627-31.
Parrish JA, Fitzpatrick TB, Tanenbaum L, Pathak MA. Photochemotherapy of psoriasis with oral methoxsalen and longwave ultraviolet light. New Engl J Med 1974; 291: 1207‑11.
Melski, JW, Tanenbaum L, Parrish JA, Fitzpatrick TB, Bleich HL. Oral methoxsalen photochemo therapy for the treatment of psoriasis: A cooperative clinical trial. J Invest Dermatol 1977; 68: 328‑35.
Kuchekar AB, Pujari RR, Kuchekar SB, Dhole SN and Mule PM. Psoriasis: A comprehensive review. Int J of Pharm & Life Sci 2011; 6: 857-77.
B.S. Tami Wong, B.A. Leon Hsu, Wilson Liao. Phototherapy in Psoriasis: A Review of Mechanisms of Action. J Cutan Med Surg 2013; 17(1): 6–12
Kochevar IE, Taylor CR, Krutmann J. Fundamentals of cutaneous photobiology and photoimmunology. In: Wolff K, Goldsmith LA, Katz SI, Gilchrest BA, Paller AS, Leffell DJ, editors. Fitzpatrick’s Dermatology in General Medicine. 7th ed. New York: McGraw Hill; 2008. p. 804.
Wong T, Hsu L, Liao W. Phototherapy in psoriasis: A review of mechanisms of action. J Cutan Med Surg 2013; 17: 6-12.
Sakuntabhai A, Sharpe GR, Farr PM. Response of psoriasis to twice weekly PUVA. Br J Dermatol 1993; 12(8): 166-71.
Karrer S, Eholzer C, Ackermann G, Landthaler M, Szeimies RM. Phototherapy of psoriasis: Comparative experience of different phototherapeutic approaches. Dermatology 2001; 202: 108-15.
de Berker DA, Sakuntabhai A, Diffey BL, Matthews JN, Farr PM. Comparison of psoralen-UVB and psoralen-UVA photochemotherapy in the treatment of psoriasis. J Am Acad Dermatol 1997; 36(4): 577-81.
Berneburg M, Herzinger T, Rampf J, Hoetzenecker W, Guenova E, Meisner C, et al. Efficacy of bath psoralen plus ultraviolet A (PUVA) vs. system PUVA in psoriasis: A prospective, open, randomized, multicentre study. Br J Dermatol 2013; 169: 704-8.
Sridhar KS, Srinivas CR, Shenoi SD. PUVA therapy for psoriasis, comparision of oral and bath water delivery of 8-MOP. Indian J Dermatol Venereol Leprol 1992; 58: 252-4.
Reynolds EF. Martinadale The extra Pharmacopia, 29th ed. The Pharmaceutical Press: London; 1989. p. 920.
Herfst MJ, De Wolff FA. Difference in availability between two brands of 8-methoxypsoralen and its impact on the clinical response in psoriatic patients. Br J Clin Pharmacol 1982; 13: 519-22.
Fischer T, Alsins J. Treatment of psoriasis with trioxsalen baths and dysprosium lamps. Acta Derm Venereol 1976; 56: 383-90.
Pai S, Srinivas CR. Bathing suit delivery of 8-methoxy psoralen for psoriasis: A double blind, placebo-controlled study. Int J Dermatol 1994; 33: 576-8.
Behrens-Williams SC, Leiter U, Schiener R, Weidmann M, Peter RU, Kerscher M. The PUVA-turban as a new option of applying a dilute psoralen solution selectively to the scalp of patients with alopecia areata. J Am Acad Dermatol 2001; 44: 248-52.
Broniarczyk-Dyla G, Wawrzycka-Kaflik A, Dubla-Berner M, Prusinska-Bratos M. Effects of psoralen-UV-A-Turban in alopecia areata. Skinmed 2006; 5: 64-8.
E. Dolezal, A. Seeber1, H. Honigsmann, A. Tanew. Correlation between bathing time and photosensitivity in 8-methoxypsoralen (8-MOP) bath PUVA. Photodermatol Photoimmunol Photomed 2000; 16: 183–85.
Jansen CT. Water temperature effect in bath-PUVA treatment. J Am Acad Dermatol 1988; 19(1): 142-3.
Anigbogu AN, Williams AC, Barry BW. Permeation Characteristics of 8-Methoxypsoralen Through Human Skin; Relevance to Clinical Treatment J. Pharm. Pharmacol 1996; 48(4): 357-66.
Tanew A, Kipfelsperger T, Seeber A, Radakovic-Fijan S, Honigsmann H. Correlation between 8-methoxypsoralen bath-water concentration and photosensitivity in bath-PUVA treatment. J Am Acad Dermatol 2001; 44: 638-42.
